GLP-1 Agonist Obesity Deal Benchmarks 2026
Market Analysis
GLP-1 receptor agonists have become the defining drug class of the decade. Semaglutide (Wegovy/Ozempic) generated $20B+ in annual revenue by 2025, making it the fastest drug to that milestone in pharma history. Tirzepatide (Mounjaro/Zepbound) achieved 22.5% weight loss in clinical trials, approaching bariatric surgery efficacy without the surgical risk.
Phase 2 GLP-1 agonist licensing deals for obesity carry median upfront payments of $935M (range $509M - $1.4B), with total deal values reaching $4.5B. The CSPC/AstraZeneca deal at $18.5B headline value and Carmot/Roche acquisition at $2.7B set the high-water marks for the category.
Oral GLP-1 formulations command significant premiums: $1.1B upfront vs $935M for injectables. The oral convenience advantage drives patient preference, primary care adoption, and payer formulary access — making oral GLP-1 assets the most sought-after in biopharma.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How much are GLP-1 obesity deals worth in 2026?
What royalty rates do GLP-1 obesity deals command?
How do oral GLP-1 deals compare to injectable GLP-1 deals?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.